Physician profile
Steven Kang
NPI 1912189051
$147,726.36
in general payments reported to CMS, 2019-2025
8 companies · $5,578 in 2025
The $5,578 reported for 2025 was more than what 81% of Blood Banking & Transfusion Medicine providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101K · 2020: $20K · 2021: $12K · 2022: $9,520 · 2023: $20.93 · 2024: $132 · 2025: $5,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,313 · Food and Beverage: $863 · Travel and Lodging: $502 · Education: $53.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,313.00 |
| Food and Beverage | $862.98 |
| Travel and Lodging | $502.47 |
| Education | $53.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $100,554.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39,728.31 | 2020-2022 | |
| Csl Behring | $5,226.19 | 2025 | Riastap |
| Gilead Sciences, INC. | $1,600.00 | 2022 | |
| Octapharma USA, INC. | $463.98 | 2019-2025 | Fibryga, Balfaxar |
| Imperative Care, INC | $72.27 | 2025 | Symphony Catheter |
| Ipsen Biopharmaceuticals, INC | $53.00 | 2024 | Onivyde |
| Genzyme Corporation | $28.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.